<?xml version="1.0" encoding="UTF-8"?>
<p>Current pharmacotherapy includes the use of corticosteroids, immunosuppressants, 5-aminosalicylates, and biological therapies to reduce the inflammatory process through the immune system [
 <xref rid="B15-molecules-25-05430" ref-type="bibr">15</xref>,
 <xref rid="B16-molecules-25-05430" ref-type="bibr">16</xref>]. However, the therapeutic approach to IBDs may require action on the three main pathophysiological componentsâ€”dysbiosis, intestinal permeability, and inflammation. It is believed that, in the future, therapies will be highly individualized, based on specific diagnoses, and identify which of these components is the dysfunction [
 <xref rid="B10-molecules-25-05430" ref-type="bibr">10</xref>,
 <xref rid="B15-molecules-25-05430" ref-type="bibr">15</xref>].
</p>
